Chan Henry Lee Sells 428 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 428 shares of the stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $257.63, for a total transaction of $110,265.64. Following the completion of the transaction, the senior vice president owned 346,554 shares of the company’s stock, valued at approximately $89,282,707.02. This represents a 0.12% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Chan Henry Lee also recently made the following trade(s):

• On Monday, June 8th, Chan Henry Lee sold 871 shares of BeOne Medicines stock. The shares were sold at an average price of $270.42, for a total transaction of $235,535.82.
• On Wednesday, May 13th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The shares were sold at an average price of $310.72, for a total transaction of $103,159.04.
• On Wednesday, April 8th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The shares were sold at an average price of $311.59, for a total transaction of $103,447.88.

BeOne Medicines Trading Down 1.6%

Shares of ONC stock opened at $263.92 on Wednesday. BeOne Medicines Ltd. – Sponsored ADR has a 52-week low of $239.25 and a 52-week high of $385.22. The stock has a market cap of $28.96 billion, a price-to-earnings ratio of 59.04 and a beta of 0.49. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. The firm has a fifty day moving average of $297.63 and a 200-day moving average of $313.49.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The company had revenue of $1.51 billion during the quarter. On average, equities research analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BeOne Medicines

A number of hedge funds have recently added to or reduced their stakes in the stock. Empowered Funds LLC bought a new stake in BeOne Medicines during the 1st quarter worth about $201,000. Bank of America Corp DE grew its holdings in BeOne Medicines by 7.0% during the 1st quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock worth $120,354,000 after acquiring an additional 26,441 shares during the last quarter. ADAR1 Capital Management LLC bought a new stake in BeOne Medicines during the 1st quarter worth about $3,475,000. EverSource Wealth Advisors LLC grew its holdings in BeOne Medicines by 16.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 369 shares of the company’s stock worth $110,000 after acquiring an additional 52 shares during the last quarter. Finally, Royal Bank of Canada grew its holdings in BeOne Medicines by 3.5% during the 1st quarter. Royal Bank of Canada now owns 70,391 shares of the company’s stock worth $20,905,000 after acquiring an additional 2,399 shares during the last quarter. Institutional investors own 48.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Barclays increased their price objective on shares of BeOne Medicines from $405.00 to $409.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Jefferies Financial Group cut shares of BeOne Medicines from a “buy” rating to a “hold” rating and dropped their target price for the stock from $420.00 to $290.00 in a research report on Monday, March 16th. Wall Street Zen upgraded shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Royal Bank Of Canada increased their target price on shares of BeOne Medicines from $425.00 to $436.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 2nd. Finally, Guggenheim increased their target price on shares of BeOne Medicines from $410.00 to $420.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $390.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.